Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Clasificación en acciones #25842
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Precio por acción
$0.40861751
Capitalización bursátil
$45.81M
Cambio (1 día)
-1.15%
Cambio (1 año)
-46.41%
País
TW
Comercio TaiRx, Inc. (6580)

Categoría

Ratio P/B de TaiRx, Inc. (6580)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de TaiRx, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de TaiRx, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US